Oral administration of TiO₂ nanoparticles during early life impacts cardiac and neurobehavioral performance and metabolite profile in an age- and sex-related manner.

"Declarations Ethics approval and consent to participateAnimal care and handling were done in compliance with the Guide for the Care and Use of Laboratory Animals [83] and approved by the Institutional Animal Care and Use Committee (IACUC) of Mispro Biotech, Research Triangle Park, NC, USA. Consent for publicationNot applicable. Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."

"Research reported in this publication was supported by the National Institute of Environmental Health Sciences of the National Institutes of Health under Award Number (NIH Grant # U01ES027254) as part of the Nanotechnology Health Implications Research (NHIR) Consortium. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The TiO2 NP used in the research presented in this publication have been procured, characterized, and provided by the Engineered Nanomaterials Resource and Coordination Core (ERCC) established at Harvard T. H. Chan School of Public Health (NIH Grant # U24ES026946) as part of the Nanotechnology Health Implications Research Consortium. The authors would like to thank Ms. Melody Markley, RTI International, for her assistance with the animal studies. Part of the characterization was performed at the Joint School of Nanoscience and Nanoengineering, a member of the Southeastern Nanotechnology Infrastructure Corridor (SENIC) and National Nanotechnology Coordinated Infrastructure (NNCI), which is supported by the National Science Foundation (Grant # ECCS-1542174). The authors would like to thank Dr. Kyle Nowlin for his assistance with generating the TEM images."